TABLE 1. Influenza vaccines — United States, 2017–18 influenza season*.
| Trade name | Manufacturer | Presentation | Age indication | Mercury (from thimerosal, µg/0.5 mL) | Latex | Route |
|---|---|---|---|---|---|---|
|
Inactivated influenza vaccines, quadrivalent (IIV4s), standard-dose†
| ||||||
| Afluria Quadrivalent |
Seqirus |
0.5 mL prefilled syringe |
≥18 years |
NR |
No |
IM§ |
| 5.0 mL multidose vial |
≥18 years (by needle/syringe)
18 through 64 years (by jet injector) |
24.5 |
No |
IM |
||
| Fluarix Quadrivalent |
GlaxoSmithKline |
0.5 mL prefilled syringe |
≥3 years |
NR |
No |
IM |
| FluLaval Quadrivalent |
ID Biomedical Corp. of Quebec (distributed by GlaxoSmithKline) |
0.5 mL prefilled syringe |
≥6 months |
NR |
No |
IM |
| 5.0 mL multidose vial |
≥6 months |
<25 |
No |
IM |
||
| Fluzone Quadrivalent |
Sanofi Pasteur |
0.25 mL prefilled syringe |
6 through 35 months |
NR |
No |
IM |
| 0.5 mL prefilled syringe |
≥3 years |
NR |
No |
IM |
||
| 0.5 mL single-dose vial |
≥3 years |
NR |
No |
IM |
||
| 5.0 mL multidose vial |
≥6 months |
25 |
No |
IM |
||
|
Inactivated influenza vaccine, quadrivalent (ccIIV4), standard-dose,† cell culture-based
| ||||||
| Flucelvax Quadrivalent |
Seqirus |
0.5 mL prefilled syringe |
≥4 years |
NR |
No |
IM |
|
|
|
5.0 mL multidose vial |
≥4 years |
25 |
No |
IM |
|
Inactivated influenza vaccine, quadrivalent (IIV4), standard-dose, intradermal¶
| ||||||
| Fluzone Intradermal Quadrivalent |
Sanofi Pasteur |
0.1 mL single-dose prefilled microinjection system |
18 through 64 years |
NR |
No |
ID** |
|
Inactivated Influenza Vaccines, trivalent (IIV3s), standard-dose†
| ||||||
| Afluria |
Seqirus |
0.5 mL prefilled syringe |
≥5 years |
NR |
No |
IM |
| 5.0 mL multidose vial |
≥5 years (by needle/syringe)
18 through 64 years (by jet injector) |
24.5 |
No |
IM |
||
| Fluvirin |
Seqirus |
0.5 mL prefilled syringe |
≥4 years |
≤1 |
Yes†† |
IM |
| 5.0 mL multidose vial |
≥4 years |
25 |
No |
IM |
||
|
Adjuvanted inactivated influenza vaccine, trivalent (aIIV3),† standard-dose
| ||||||
| Fluad |
Seqirus |
0.5 mL prefilled syringe |
≥65 years |
NR |
Yes†† |
IM |
|
Inactivated Influenza Vaccine, trivalent (IIV3), high-dose
§§
| ||||||
| Fluzone High-Dose |
Sanofi Pasteur |
0.5 mL prefilled syringe |
≥65 years |
NR |
No |
IM |
|
Recombinant Influenza Vaccine, quadrivalent (RIV4)
¶¶
| ||||||
| Flublok Quadrivalent |
Protein Sciences |
0.5 mL prefilled syringe |
≥18 years |
NR |
No |
IM |
|
Recombinant Influenza Vaccine, trivalent (RIV3)
¶¶
| ||||||
| Flublok |
Protein Sciences |
0.5 mL single-dose vial |
≥18 years |
NR |
No |
IM |
|
Live Attenuated Influenza Vaccine, quadrivalent (LAIV4)*** (not recommended for use during the 2017–18 season)
| ||||||
| FluMist Quadrivalent | MedImmune | 0.2 mL single-dose prefilled intranasal sprayer | 2 through 49 years | NR | No | NAS |
Abbreviations: ACIP = Advisory Committee on Immunization Practices; ID = intradermal; IM = intramuscular; NAS = intranasal; NR = not relevant (does not contain thimerosal).
* Immunization providers should check Food and Drug Administration–approved prescribing information for 2017–18 influenza vaccines for the most complete and updated information, including (but not limited to) indications, contraindications, warnings, and precautions. Package inserts for U.S.-licensed vaccines are available at https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm093833.htm. Availability of specific products and presentations might change and differ from what is described in this table and in the text of this report.
† Standard dose intramuscular IIVs contain 15 µg of each vaccine HA antigen (45 µg total for trivalents and 60 µg total for quadrivalents) per 0.5 mL dose.
§ For adults and older children, the recommended site for intramuscular influenza vaccination is the deltoid muscle. The preferred site for infants and young children is the anterolateral aspect of the thigh. Specific guidance regarding site and needle length for intramuscular administration is available in the ACIP General Best Practice Guidelines for Immunization, available at https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html.
¶ Quadrivalent inactivated influenza vaccine, intradermal: a 0.1-mL dose contains 9 µg of each vaccine HA antigen (36 μg total).
** The preferred injection site is over the deltoid muscle. Fluzone Intradermal Quadrivalent is administered per manufacturer’s instructions using the delivery system included with the vaccine.
†† Syringe tip cap might contain natural rubber latex.
§§ High-dose IIV3 contains 60 μg of each vaccine antigen (180 μg total) per 0.5 mL dose.
¶¶ RIV contains 45 μg of each vaccine HA antigen (135 μg total for trivalent 180 μg total for quadrivalent) per 0.5 mL dose.
***ACIP recommends that FluMist Quadrivalent (LAIV4) not be used during the 2017–18 season.